The treatment landscape for advanced gastric cancer is rapidly evolving and expanding. This expert commentary offers an overview of current recommended biomarker testing and corresponding treatment strategies as well as insights on adverse event management to provide optimal outcomes for patients with advanced gastric cancer.
Oncology NPs, PAs, and nurses
This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421GW-CT